Skip to Content
MilliporeSigma

L5545

Levosimendan

≥98% (HPLC), calcium sensitizer, powder

Synonym(s):

(-)-OR-1259, (R)-Simendan, 2-[2-[4-[(4R)-1,4,5,6-Tetrahydro-4-methyl-6-oxo-3-pyridazinyl]phenyl]hydrazinylidene]-propanedinitrile, OR 1259, R)-((4-(1,4,5,6-Tetrahydro-4-methyl-6-oxo-3-pyridazinyl)phenyl)hydrazono) propanedintrile

Sign In to View Organizational & Contract Pricing.

Select a Size

Pricing and availability is not currently available.

About This Item

Empirical Formula (Hill Notation):
C14H12N6O
CAS Number:
Molecular Weight:
280.28
UNSPSC Code:
12352202
PubChem Substance ID:
NACRES:
NA.77
MDL number:
Assay:
≥98% (HPLC)
Form:
powder
Quality level:

Skip To

Technical Service
Need help? Our team of experienced scientists is here for you.
Let Us Assist

Product Name

Levosimendan, ≥98% (HPLC)

SMILES string

C[C@@H]1CC(=O)NN=C1c2ccc(N\N=C(\C#N)C#N)cc2

InChI key

WHXMKTBCFHIYNQ-SECBINFHSA-N

InChI

1S/C14H12N6O/c1-9-6-13(21)19-20-14(9)10-2-4-11(5-3-10)17-18-12(7-15)8-16/h2-5,9,17H,6H2,1H3,(H,19,21)/t9-/m1/s1

assay

≥98% (HPLC)

form

powder

optical activity

[α]/D -500 to -650°, c = 0.5 in THF

color

yellow

solubility

DMSO: ≥20 mg/mL

storage temp.

room temp

Quality Level

Related Categories

Compare Similar Items

View Full Comparison

Show Differences

1 of 4

This Item
SML1179SML1563SML2208
assay

≥98% (HPLC)

assay

≥98% (HPLC)

assay

≥98% (HPLC)

assay

≥98% (HPLC)

form

powder

form

powder

form

powder

form

powder

Quality Level

100

Quality Level

100

Quality Level

100

Quality Level

-

storage temp.

room temp

storage temp.

2-8°C

storage temp.

2-8°C

storage temp.

2-8°C

solubility

DMSO: ≥20 mg/mL

solubility

DMSO: 10 mg/mL, clear

solubility

DMSO: 20 mg/mL, clear

solubility

DMSO: 2 mg/mL, clear

color

yellow

color

white to beige

color

white to light brown

color

white to beige

Application

Levosimendan has been used for screening its anti-human immunodeficiency virus type 1 (HIV-1) property.[1] It has also been used for screening its cytotoxic effects in TP53 mutant and wild-type lung adenocarcinoma cell lines[2]

Biochem/physiol Actions

Levosimendan has a potential to inhibit both acute human immunodeficiency virus type 1 (HIV-1) replication and the reactivation of latent HIV-1 proviruses. Therefore, it is considered to be a promising anti-HIV-1 agent.[1]
Levosimendan is a calcium sensitiser.
Levosimendan is a calcium sensitiser. The compound increases the sensitivity of the heart to calcium, thus increasing cardiac contractility without a rise in intracellular calcium. Levosimendan binds to cardiac troponin C in a calcium-dependent manner and stabilizes troponin C. This is followed by actin-myosin cross-bridges, without increasing myocardial consumption of ATP. Additionally the compound acts as vasodilator by opening an ATP-sensitive potassium channels. Levosimendan is a drug used for treatment of congestive heart failure. Also it can be used to treat calcium channel blocker overdose.

pictograms

Exclamation mark

signalword

Warning

Hazard Classifications

Acute Tox. 4 Dermal - Acute Tox. 4 Inhalation - Acute Tox. 4 Oral

Storage Class

11 - Combustible Solids

wgk

WGK 3

flash_point_f

Not applicable

flash_point_c

Not applicable


Choose from one of the most recent versions:

Certificates of Analysis (COA)

Lot/Batch Number

Don't see the Right Version?

If you require a particular version, you can look up a specific certificate by the Lot or Batch number.

Already Own This Product?

Find documentation for the products that you have recently purchased in the Document Library.

Visit the Document Library

Saraswati Kache et al.
Pediatric research, 88(5), 705-716 (2020-07-08)
Fewer children than adults have been affected by the COVID-19 pandemic, and the clinical manifestations are distinct from those of adults. Some children particularly those with acute or chronic co-morbidities are likely to develop critical illness. Recently, a multisystem inflammatory
Matti Adam et al.
Scientific reports, 5, 9704-9704 (2015-04-14)
Treatment of decompensated heart failure often includes administration of levosimendan. Myeloperoxidase (MPO) is released during polymorphonuclear neutrophil (PMN) degranulation, and mediates dysregulation of vascular tone in heart failure. We evaluated the effects of levosimendan-treatment on MPO in patients with acute
Claes-Håkan Bergh et al.
European journal of heart failure, 12(4), 404-410 (2010-03-26)
The aim of this study is to compare the effects of a 24 h intravenous infusion of levosimendan and a 48 h infusion of dobutamine on invasive haemodynamics in patients with acutely decompensated chronic NYHA class III-IV heart failure. All
Screening of an FDA-approved compound library identifies levosimendan as a novel anti-HIV-1 agent that inhibits viral transcription
Hayashi T, et al.
Antiviral research, 146, 76-85 (2017)
Julia Hasslacher et al.
Critical care (London, England), 15(4), R166-R166 (2011-07-14)
Levosimendan is an extensively investigated inodilator showing also cardioprotective and antiinflammatory effects. The aim of our study was to explore the influence of levosimendan on polymorphonuclear leucocytes (PMN), a main source of reactive oxygen species, in vitro and in patients

Questions

Reviews

No rating value

Active Filters

Our team of scientists has experience in all areas of research including Life Science, Material Science, Chemical Synthesis, Chromatography, Analytical and many others.

Contact Technical Service